The leading cause of heart disease in developed countries is coronary atherosclerosis,
which is not simply a result of ageing but a chronic inflammatory process that can lead to …

Protease-activated receptor 4 (PAR4) is a G-protein coupled receptor that is expressed on
human platelets and activated by the coagulation enzyme thrombin. PAR4 plays a key role …

Ischemic cardiovascular diseases have a high incidence and high mortality worldwide.
Therapeutic advances in the last decades have reduced cardiovascular mortality, with …

Purpose To assess whether the newly designed small-molecule oral P-selectin inhibitor 3 S-
1, 2, 3, 4-tetrahydro-β-carboline-3-methyl aspartyl ester (THCMA) as a nanomedicine …

Background Aspirin and platelet P2Y 12 inhibitors, such as ticagrelor, suboptimally inhibit
microvascular thrombosis during ST-elevation myocardial infarction. Glycoprotein (GP) …

Background New antithrombotic therapies with less effect on bleeding are needed for
coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque–mediated …

BACKGROUND Healed plaques are frequently found in patients with acute coronary
syndrome, but the prognostic value is debatable. This study investigated the clinical features …

During an acute coronary syndrome, atherosclerotic plaque rupture triggers platelet
activation and thrombus formation, which may completely occlude a coronary artery leading …

Background. The increased thrombotic risk in patients with acute coronary syndrome (ACS)
and diabetes highlights the need for adequate antithrombotic protection. We aimed to …

Background: Inappropriate activation and aggregation of platelets can lead to arterial
thrombosis. Thrombin is the most potent platelet agonist that activates human platelets via …